Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: New approaches for the design of potential tocolytics for preterm labor

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 999-1003

  Chan, W Y ^a   Wo, Nga Ching ^a   Cheng, Ling Ling ^b   Manning, Maurice ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYTOCIN; OXYTOCIN RECEPTOR; UTERUS SPASMOLYTIC AGENT; VASOPRESSIN RECEPTOR; OXYTOCIN ANTAGONIST; SYNTHETIC PEPTIDE; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG DESIGN; FEMALE; PREGNANCY; PREMATURE LABOR; RAT; STRUCTURE ACTIVITY RELATION; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; TOCOLYSIS;

ANIMALS; DRUG DESIGN; FEMALE; OBSTETRIC LABOR, PREMATURE; OXYTOCIN; PREGNANCY; RATS; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP; TOCOLYTIC AGENTS;

EID: 0030136570     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. ADAMS, M. M.: The continuing challenge of preterm delivery. J.A.M.A. 273: 739-740, 1995.
2. ANDERSON, L. F., LYNDRUP, J., AKERLUND, M. AND MELIN, P.: Oxytocin receptor blockade: A new principle in the treatment of preterm labor? Am. J. Perinat. 6: 196-199, 1989.
3. BOSSMAR, T., AKERLUND, M., FANTONI, G., SZAMATOWICZ, J., MELIN, P. AND MAGGI, M.: Receptor for and myometrial responses to oxytocin and vasopressin in preterm and term human pregnancy: Effects of the oxytocin antagonist Atosiban. Am. J. Obstet. Gynecol. 171: 1634-1642, 1994.
4. CHAN, W. Y. AND CHEN, D. L.: Myometrial oxytocin receptors and prostaglandin in the parturition process in the rat. Biol. Reprod. 46: 58-64, 1992.
5. CHAN, W. Y. AND KELLEY, N.: A pharmacologic analysis on the significance of the chemical functional groups of oxytocin to its oxytocic activity and on the effect of magnesium on the in vitro and in vivo oxytocic activity of neurohypophysial hormones. J. Pharmacol. Exp. Ther. 156: 150-158, 1967.
6. 1a receptors are involved in uterine contractions. The First Joint World Congress of Neurohypophysis and Vasopressin. Nasu, Tochigi, Japan, Abstract P-45, 1995.
7. CHENG, L. L., KLIS, W. A., OLMA, A., SAWYER, W. H., WO, N. C., CHAN, W. Y. AND MANNING, M.: Position 5 modifications of vasopressin and oxytocin antagonists enhance OT receptor selectivity. In Peptides, ed. by P. Kaumaya and R. S. Hodges, ESCOM, Leiden, in press, 1996.
8. DEKANSKI, J.: The quantitative assays of vasopressin. Br. J. Pharmacol. 7: 567-572, 1952.
9. DU VIGNEAUD, V., DENNING, G. S. JR., DRABAREK, S. AND CHAN, W. Y.: The synthesis and pharmacology study of 4-decarboxamide-oxytocin (4-α-amino-butyric acid-oxytocin) and 5-decarboxamide-oxytocin (5-alanine-oxytocin). J. Biol. Chem. 239: 472-478, 1964.
10. DYKES, D. F., NESTOR, J. J., JR., FERGER, M. F. AND DU VIGNEAUD, V.: [1-β-Mercapto-β, β-diethylpropionic acid]-8-lysine-vasopressin, a potent inhibitor of 8-lysine- vasopressin and of oxytocin. J. Med. Chem. 17: 250-252, 1974.
11. 9]OVT: A selective oxytocin receptor ligand. Eur. J. Pharmacol. 147: 197-207, 1988.
12. FUCHS, A. R., FUCHS, F. AND HUSSLEIN P.: Oxytocin receptors and human parturition: A dual role for oxytocin in the initiation of labor. Science 215: 1396-1398, 1982.
13. GOODWIN, T. M., PAUL, R., SILVER, H., SPELLACY, W., PARSONS, M., CHEZ, R., HAYASHI, R., VALENZUELA, G., GREASY G. W. AND MERRIMAN, R.: The effect of the oxytocin antagonist Atosiban on preterm uterine activity in the human. Am. J. Obstet. Gynecol. 170: 475-478, 1994.
14. HASE. S , SCHWARTZ, I. L. AND WALTER, R.: Further studies of the role of the asparagine residue in oxytocin: Synthesis and biological properties of (5α,y-diaminobutyric acid)oxytocin. J. Med. Chem. 15: 126-128, 1972.
15. 5 position shed light on hormone-oxytocin receptor interactions. Int. J. Peptide Protein Res. 38: 32-37, 1991.
16. HOLTON, P.: A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract Br. J. Pharmacol. 3: 328-334, 1948.
17. HRUBY, V. J.: The relationship of conformation to biological action of oxytocin and its analogues. In Oxytocin: Clinical and Laboratory Studies, ed. by J. A. Amico and A G. Robinson, pp. 405-414, Elsevier, Amsterdam, 1985.
18. HRUBY, V. J.: Implications of the X-ray structure of deamino-oxytocin to agonist/ antagonist-receptor interactions. Trends Pharmacol. Sci. 8: 336-339, 1987.
19. KRUSZYNSKI, M., LAMMEK, B., MANNING, M., SETO, J., HALDAR, J. AND SAWYER, W. H.: [1-(β-Mercapto-β-β-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine]- arginine-vasopressin and [1-(β-mercapto-β-β-cyclopentamethyl-enepropionic acid)]arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin. J. Med. Chem. 23: 364-368, 1980.
20. LEFEBVRE, D. L., GIAID, A., BENNETT, H., LARIVIERE, R. AND ZINGG H. H.: Oxytocin gene expression in rat uterus. Science 256: 1553-1555, 1992.
21. MACORMICK, M. C.: The contribution of low birth weight to infant mortality and morbidity. N. Engl J. Med. 312: 82-90, 1985.
22. MAIN, D. M.: The epidemiology of preterm birth. Clin. Obstet. Gynecol. 31: 521-532, 1988.
23. MANNING, M., KRUSZYNSKI, M., BANKOWSKI, K., OLMA, A., LAMMEK, B., CHENG, L. L , KLIS, W. A., SETO, J., HALDAR, J. AND SAWYER, W. H.: Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin. J. Med. Chem. 32: 382-391, 1989.
24. MANNING, M., MITEVA, K., PANCHEVA, S., STOEV, S., WO, N. C. AND CHAN, W. Y.: Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: Comparisons with Atosiban. Int. J. Peptide Protein Res. 46: 244-252, 1995.
25. MANNING, M., OLMA, A., KLIS, W., KOLODZIEJCZYK, A., NAWROCKA, E., MISICKA, A., SETO, J. AND SAWYER, W. H.: Carboxy terminus of vasopressin required for activity but not binding. Nature 308: 652-653, 1984.
26. MELIN, P., TROJNAR, J., JOHANSSON, B., VILHARDT, H. AND AKERLUND, M.: Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrin. 111: 125-131, 1986.
27. MUNSICK, R. A.: Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormones and analogues. Endocrinology 66: 451-457, 1960.
28. SAWYER, W. H.: Biologic assays for oxytocin and vasopressin. Methods Med. Res. 9: 210-219, 1961.
29. SCHILD, H. O.: pA, a new scale for the measurement of drug antagonism. Br. J. Pharmacol. 2: 189-206, 1947.
30. THORNTON, S. AND SMITH, S. K.: The physiological basis for administration of oxytocin antagonists in preterm labour. J. Royal Soc. Med. 88: 166P-170P, 1995.
31. WALTER, R.: Identification of sites in oxytocin involved in uterine receptor recognition and activation. Fed. Proc. 36: 1872-1878, 1977.